GLYCOMIMETICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.2889 USD | -3.51% |
|
+10.10% | -87.76% |
| 05-09 | GlycoMimetics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 05-07 | Capital One Downgrades GlycoMimetics to Equalweight, Price Target at $0.50 | MT |
Presentation Operator MessageOperator (Operator)Good day, and welcome to GlycoMimetics 2021 An...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
GlycoMimetics, Inc. is a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers, including acute myeloid leukemia (AML) and for inflammatory diseases. It is developing a pipeline of glycomimetics, which are small molecules that mimic the structure of carbohydrates involved in biological processes, to inhibit disease-related functions of carbohydrates, such as the roles they play in inflammation, cancer and infection. Its drug candidates include Uproleselan, GMI-1687, Galectin Antagonists and GMI-1359. It is developing Uproleselan, a specific E-selectin antagonist, to be used in combination with chemotherapy to treat patients with AML, a life-threatening hematologic cancer, and potentially other hematologic cancers. It has designed an antagonist of E-selectin, GMI-1687, that is suitable for subcutaneous administration. GMI-1359 is a drug candidate that simultaneously targets both E-selectin and a chemokine receptor (CXCR4).
Calendar
31/07/2024
- Q2 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
0.2994
USD
Average target price
0.75
USD
Spread / Average Target
+150.50%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -87.76% | 19.3M | |
| +9.58% | 115B | |
| +12.41% | 106B | |
| -2.59% | 21.96B | |
| -12.38% | 21.87B | |
| -5.29% | 19.21B | |
| -3.35% | 18.08B | |
| -38.57% | 17.71B | |
| +7.51% | 14.32B | |
| +35.67% | 12.42B |
- Stock Market
- Equities
- GLYC Stock
- News GlycoMimetics, Inc.
- Transcript : GlycoMimetics, Inc. - Shareholder/Analyst Call
